Showing results (111-120 of 331) with videos related to

Sort By:
Pageof 34
Cancer Immunology Research|May 1, 2020
Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 TherapyKaustav P Shah, Haocan Song, Fei Ye, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2019
Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver MetastasisDouglas B Johnson, Riyue Bao, Kristin K Ancell, et al.
Circulation Research|May 3, 2021
Mechanisms of Cardiovascular Toxicities Associated With ImmunotherapiesAlan H Baik, Olalekan O Oluwole, Douglas B Johnson, et al.
British Journal of Clinical Pharmacology|June 17, 2020
Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapyBrendan L Mangan, Renee K McAlister, Justin M Balko, et al.
The Oncologist|April 16, 2021
Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II StudyCaroline A Nebhan, Douglas B Johnson, Ryan J Sullivan, et al.
The Oncologist|September 27, 2025
Chatbot assistance in precision oncology treatment decision-makingHannah Burnette, Kylie Fletcher, Christine Micheel, et al.
Cancer|October 4, 2019
Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitorsLaura X Wang, Henry T Quach, Nikil V Moodabigil, et al.
Journal for Immunotherapy of Cancer|May 22, 2020
COVID-19 and immune checkpoint inhibitors: initial considerationsRyan J Sullivan, Douglas B Johnson, Brian I Rini, et al.
The Oncologist|November 23, 2020
A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain MetastasisJ Randall Patrinely, Elisa Funck-Brentano, Khang Nguyen, et al.
Pageof 34